Peripheral ulcerative keratitis (PUK) is a unilateral crescent-shaped stromal inflammation that has long been associated with collagen vascular disease such as rheumatoid arthritis (RA)\(^1\). PUK in RA generally appears late in the disease course, and usually signals worsening of the systemic disease\(^2,3\). Tumor necrosis factor-α inhibitor (TNFi) has been reported to be effective in RA-associated PUK cases refractory to conventional immunomodulatory therapy\(^4,5\).

A 58-year-old woman with a 35-year history of RA (Figure 1) presented to our clinic with ocular pain and redness. Her symptoms had occurred 3 weeks before, and she had been treated with eyedrops at a local clinic. Since 2006, she had been treated with etanercept (50 mg/week) and leflunomide (10 mg/day) for RA. Ocular examination revealed circumferential PUK (Figure 2A). The patient was initially treated with high-dose prednisolone (1 mg/kg); however, her condition worsened within 1 week (Figure 2B). Although previously treated with TNFi, her RA symptoms and PUK worsened, after which treatment was altered to tocilizumab (162 mg biweekly). After 3 weeks, corneal melting was rapidly progressive (Figure 2C). However, she refused further surgical treatment.

Despite improvements in new immunomodulatory therapy, the outcome of PUK depends on the accompanying disease, as well as timely diagnosis and treatment\(^2\). The authors suggest that this patient’s refractory response to treatment was due to the progression of symptoms prior to starting aggressive treatment. This image highlights the importance of close communication between ophthalmologists and rheumatologists for early diagnosis of PUK.

REFERENCES
